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Abstract
New onset thrombocytopenia and multiple organ failure (TAMOF)
presages poor outcome in critical illness. Patients who resolve
thrombocytopenia by day 14 are more likely to survive than those
who do not. Patients with TAMOF have a spectrum of micro-
angiopathic disorders that includes thrombotic thrombocytopenic
purpura (TTP), disseminated intravascular coagulation (DIC) and
secondary thrombotic microanigiopathy (TMA). Activated protein C
is effective in resolving fibrin-mediated thrombosis (DIC); however,
daily plasma exchange is the therapy of choice for removing
ADAMTS 13 inhibitors and replenishing ADAMTS 13 activity
which in turn resolves platelet: von Willebrand Factor mediated
thrombosis (TTP/secondary TMA).
Thrombocytopenia-associated multiple organ
failure: what is it?
New onset thrombocytopenia in the critically ill patient has
been established as an important independent risk factor for
the development of multiple organ failure. Intensive care unit
non-survivors commonly have thrombocytopenia out to 14 days
whereas survivors do not [1-8]. It has long been established
that thrombocytopenia at admission to the intensive care unit is
a risk factor for mortality; however, this observation supports
the concept that ongoing thrombocytopenia over time can be
associated with pathological consequences similar to, for
example, ongoing hypotension over time.
Laboratory and clinical studies have now confirmed that
thrombocytopenia-associated multiple organ failure (TAMOF)
is a thrombotic microangiopathic syndrome that can be
defined by a spectrum of pathology that includes thrombotic
thrombocytopenic purpura (TTP), secondary thrombotic
microangiopathy (TMA), and disseminated intravascular
coagulation (DIC). All three of these pathophysiological
states have been reported in critically ill patients who
developed endotheliopathy caused by exposure to
cardiopulmonary bypass, infection, transplantation, radiation,
chemotherapy, auto-immune disease, and transplantation
medications. The preponderance of clinical evidence to date
suggests that the use of plasma exchange for TTP and
secondary TMA, and anticoagulant protein therapies, such as
activated protein C, for DIC results in reversal of TAMOF and
improved survival [9-51].
Understanding pathological coagulation and
systemic endotheliopathy
Pro-thrombotic and anti-fibrinolytic responses, which are
helpful during focal injury, may be injurious in the setting of
systemic endothelial injury and are manifested by thrombo-
cytopenia, systemic thrombosis, and multiple organ failure.
Critically ill patients develop systemic endothelial micro-
angiopathic disease after many types of systemic insults
(Table 1). The pathophysiology of these thrombotic micro-
angiopathies caused by systemic endothelial inury can be
characterized as part of a spectrum of three phenotypes, TTP
(Figure 1), consumptive DIC (Figure 2), and non-consumptive
secondary TMA (Figure 3) [30-34].
Thrombotic thrombocytopenic purpura
TTP has been described in two forms, acute and chronic
relapsing (Table 2). It is described clinically as the
constellation of fever, thrombocytopenia, abnormal mental
status and or seizures, renal dysfunction, and microangio-
pathic hemolysis indicated by an elevated lactate dehydro-
genase (LDH). There has been significant improvement in
understanding of this disease in recent years. The acute form,
which accounts for the majority of cases, occurs when
antibody production against the von Willebrand factor (vWF)-
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cleaving proteinase (also called ADAMTS 13) destroys vWF
cleaving proteinase activity (Figure 1). These patients have
<10% of normal ADAMTS 13 activity. This leads to an inability
to cleave unusually large and large multimers to their smaller,
less thrombogenic multimers. Because these antibodies are
produced in the presence of disease states associated with
increased shear stress, the circulating large vWF multimers
open and participate with near 100% efficiency in deposition
of platelet thrombi. Because shear stress is greatest in the
brain and kidney, these organs are most involved, although
multiple organs are involved as well [9-16]. The less common
but chronic relapsing form of TTP occurs in patients with a
deficiency in ADAMTS 13 activity. These patients become ill
during periods of systemic illness associated with increased
microvascular shear stress. Fibrin thrombosis is involved as
well. There is also a reduction in tissue factor pathway inhibitor
(TFPI) levels without an increase in tissue factor levels, and an
increase in plasminogen activator inhibitor type I (PAI-1) levels
as well.
Disseminated intravascular coagulation
DIC is a consumptive syndrome (consuming pro-coagulant
factors such as fibrinogen, Table 2) that is represented in its
most severe form by purpura fulminans and in its least severe
form by abnormalities in platelet count and prothrombin time
(PT)/activated partial thromboplastin time (aPTT). It is
described clinically as the constellation of thrombocytopenia,
decreased factors V and X, decreased fibrinogen and
increased D-dimers. The depletion of factors and fibrinogen
explains the common association with prolonged PT/aPTT.
There has been a significant improvement in understanding of
thrombosis in patients with DIC syndrome in recent years.
When observing and diagnosing the thrombotic process, it is
important to understand how increased coagulation is
occurring despite prolongation of PT/aPTT. We have been
trained to think that prolonged PT/aPTT and reduced platelet
count are indicative of a greater tendency to bleeding. How
can prolonged PT/aPTT occur when a patient is in a pro-
coagulant rather than an anti-coagulant state? How can
investigators recommend heparin therapy for patients with
DIC when the patient has thrombocytopenia and a prolonged
PT/aPTT? PT and aPTT are dependent on coagulation factors
Table 1
Conditions associated with thrombocytopenia-associated
multiple organ failure
Cancer
Transplantation
Cardiovascular surgery/cardiopulmonary bypass
Autoimmune disease
Systemic infection
Vasculitis
Toxins
Cyclosporine A
FK 506
Chemotherapy
Radiation
Ticlopidine
Hemolytic Uremic Syndrome variant syndromes
Figure 1
Systemic inflammation results in systemic coagulation. Thrombotic thrombocytopenuc purpura (TTP) is a microangiopathy phenotype characterized
by ADAMTS 13 deficiency. Left: Platelets attach to ultra large vWF multimers. Because vWF-CP (ADAMTS 13) is inhibited this leads to massive
vWF:platelet thrombosis (right). Ab, antibody; CP, cleaving protease; vWF, von Willebrand factor.Page 3 of 8
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and fibrinogen; PT and aPTT increase when these proteins are
reduced and decrease when these proteins are increased.
The tissue factor-factor VII pathway, not the factor XII
pathway, is responsible for thrombosis in patients with DIC
caused by systemic bacterial infection. When released into
the circulation by monocyte micro-vesicles or exposed by
injured endothelium, tissue factor forms a complex with factor
VII and initiates thrombosis (Figure 2). If tissue factor
promotes consumption of clotting factors to the point that
factors V and X and fibrinogen are depleted, then the patient
develops a prolonged PT/aPTT. The endogenous anti-
coagulant system is also reduced and, paradoxically, contri-
butory to thrombosis in DIC. Protein C, protein S, and
antithrombin III are significantly reduced in patients with DIC.
Newborns with a congenital absence of protein C, protein S,
or antithrombin III can develop spontaneous purpura
fulminans, which is fatal if not treated with fresh frozen
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Figure 2
Disseminated intravascular coagulation (DIC) is a microangiopathy phenotype characterized by increased tissue factor (TF) and plasminogen
activator inhibitor type I (PAI-1), unopposed by the anticoagulant proteins TFPI, protein C, antithrombin III, and prostacyclin. The severest forms
also have an ADAMTS 13 deficiency. Tissue factor activates factor VII (left), leading to massive consumptive fibrin thrombosis (right). VII, factor VII;
vWF, von Willebrand factor.
Figure 3
Secondary thrombotic microangiopathy (TMA) has a phenotype characterized by decreased ADAMTS 13, and increased plasminogen activator
inhibitor type I (PAI-1) and von Willebrand factor (vWF) levels with normal or high fibrinogen levels. Platelets attach to increased large vWF
multimers and form thrombi in the presence of decreased PAI-I activity (left), leading to systemic platelet thrombi with delayed fibrinolysis (right).
CP, cleaving protease; TF, tissue factor; TFPI, tissue factor pathway inhibitor; vWF-CP, ADAMTS 13.plasma infusion to replace the anti-coagulant proteins [35,42-
44,47,48]. An increased anti-fibrinolytic system also
contributes to sustained thrombosis in patients with DIC.
Tissue plasminogen activator levels initially increase;
however, within 12 to 24 hours the patients develop
increased plasminogen activator inhibitor-1 antigen levels and
a decrease in plasminα2-anti-plasmin production, indicative of
a hypo-fibrinolytic state [10].
Non-consumptive secondary thrombotic
microangiopathy
Non-consumptive secondary TMA occurs in critically ill
patients with secondary TTP/Hemolytic Uremic Syndrome-
like syndromes (Tables 1 and 2). It is identified clinically by
the constellation of clinical criteria present with the primary
form (TTP) with the exception of one; there is little evidence
of hemolysis on peripheral smear [19,20,22-24]. The majority
of patients with TMA have thrombocytopenia associated
multiple organ failure with a normal or mildly elevated
PT/aPTT. These patients have increased or normal levels of
factors V, VIII, and X and fibrinogen but also have increased
D-dimers. They also have very thrombogenic ultra-large vWF
multimers, decreased ADAMTS 13 activity (<57% but rarely
<10% as is seen in TTP), ADAMTS 13 inhibitors, and
increased PAI-1 activity but normal TFPI activity and absent
tissue factor activity (Figure 3). The systemic endothelium is
in a platelet pro-coagulant and fibrin anti-fibrinolytic state but,
unlike DIC, it is not in a fibrin pro-coagulant state. Thus,
consumption of pro-coagulant factors is not observed to the
degree noted during DIC.
Choosing a therapy to treat thrombocytopenia-
associated multiple organ failure
There is an array of non-specific and specific therapies
available to the intensivist for management of the critically ill
patient with TAMOF (Figure 4, Table 3). TTP mortality was
close to 100% before Bell and colleagues [17] demonstrated
that the use of steroids and plasma exchange therapy
reduced mortality to 10%. Interestingly, many of the patients
treated in this way had evidence of DIC, and histology that
showed fibrin and inflammatory cell lesions, and not only
platelet-vWF thrombi, in the microvascular thrombi. These
patients were defined as having TTP/HUS by a process of
elimination when no other cause(s) (for example, infection,
toxin, disease, and so on) could be found to explain the
underlying microangiopathy. Rock and colleagues [18] also
demonstrated that a median of 18 days of plasma exchange
was superior to plasma infusion in improving survival in a
cohort of patients with TTP and a normal PT/aPTT.
Acute TTP is treated successfully as follows. Because the
process can be mediated by antibodies to vWF-cleaving
proteinase, a trial of steroid therapy is reasonable as a first
step. Daily plasma exchange should be used if resolution is
not attained within 24 hours of steroid therapy. Plasma
exchange is more effective than plasma infusion because
antibodies can be removed from the recipient, and ADAMTS
13 can be replaced by the donor plasma. In patients who are
recalcitrant to fresh frozen plasma, some recommend use of
cryo-preserved supernatant (fresh frozen plasma minus
cryoprecipitate) or solvent detergent treated (soluble
Critical Care    Vol 10 No 6 Nguyen and Carcillo
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Table 2
Diagnosing the pathophysiology of thrombocytopenia-associated multiple organ failure
Diagnostic criteria Treatment
TTP Fever Steroids for 24 hours
Thrombocytopenia Within 30 hours perform 1½ volume plasma exchange then 1 volume daily 
Increased LDH until resolution of thrombocytopenia (median 18 days [18])
Schistocytes >5% If recalcitrant use cryopreserved supernatant
Neurological and renal dysfunction If continues at 28 days use vincristine
DIC Thrombocytopenia Reverse shock and underlying disease (increase flow with fluids and 
Decreased factors V and X, and fibrinogen consider vasodilators – nitroglycerin, milrinone, pentoxyfilline)
Decreased antithrombin III and protein C Replace clotting factors with FFP, cryoprecipitate and platelets via plasma 
Increased D-dimers infusion or plasma exchange
Prolonged PT/aPTT Anticoagulate with heparin, protein C, activated protein C, antithrombin III, 
or prostacyclin
Use fibrinolytics for life or limb threatening thrombosis. Remember to keep 
PT/aPTT and platelets normal when giving fibrinolytics
Give anti-fibrinolytics if life threatening bleeding (rarely needed when 
PT/aPTT and platelet counts are maintained)
Secondary  Thrombocytopenia Remove source of secondary TMA
TMA Increased LDH Activated protein C for adult severe sepsis [26]
Normal or elevated fibrinogen TTP based plasma exchange (median 9 days [51]; median 12 days for 
<5% schistocytes children (Nguyen, 2006, submitted)
Multiple organ failure
aPTT, activated partial thromboplastin time; DIC, disseminated intravascular coagulation; FFP, fresh frozen plasma; LDH, lactate dehydrogenase;
PT, prothrombin time; TMA, thrombotic microangiopathy; TTP, thrombotic thrombocytopenic purpura.detergent) plasma because these plasma products are poor in
large vWF multimers. Plasma exchange therapy is most
effective when implemented within the first 24 hours of
disease, and is required for an average of 15.8 days to restore
platelet counts without recrudescence of thrombocytopenia.
The endpoint of therapy is resolution of thrombocytopenia
(attainment of a platelet count greater than 150,000) and no
further deterioration of neurological status. Vincristine is
recommended to stop antibody production in patients who are
recalcitrant to 28 days of plasma exchange therapy. Chronic
relapsing TTP, though much less common, requires chronic
plasma infusion therapy after resolution of the acute episode.
Plasma infusions may be required on a monthly basis. The
benefits of these therapies are considerable. The short-term
risks associated with plasma exchange therapy include the
need for a large bore intravenous catheter, hypocalcemia
secondary to citrate requiring calcium replacement,
hypotension requiring inotropes or vasopressors in patients
with shock, awakening requiring increased use of sedation in
some patients, and secondary catheter-related infections. The
long-term risks include blood borne virus exposure.
DIC is a primary determinant of outcome in critically ill
patients. The most important determinant of outcome is
aggressive fluid resuscitation, restoration of normal or hyper-
dynamic circulation, and removal of any nidus of infection.
With this approach, DIC is now the least common
manifestation of organ failure in patients with MOF. However,
despite reversal of shock, there are still patients who have
DIC and coagulopathy is a predictor of mortality if it persists.
The present mainstay of therapy for DIC is replacement of
plasma until PT/aPTT is corrected. This approach could be
theoretically counterproductive in some patients. Although
PT/aPTT can improve as antithrombin III, protein C and
protein S are replaced, some have wondered whether conco-
mitant replacement of coagulation factors in fresh frozen
plasma is ‘fueling the fire’. For this reason, many investigators
who use plasma infusion recommend concomitant heparin
infusion to allow ongoing anti-coagulation. In countries where
antithrombin III or protein C concentrate are available,
physicians may use these concentrates in place of, or in
combination with, plasma infusion. Both approaches have
been shown to be effective in reversing DIC. An international
multicenter study in adults comparing use of activated protein
C to standard therapies found a reduction in 28 day mortality
from 30.8% to 26.3% in adults with severe sepsis [26].
Although patients with platelet counts less than 30,000/mm3
were excluded from this study, the greatest benefit was found
in patients with platelets counts <100,000 and elevated
thrombin-antithrombin complexes diagnostic of DIC.
TFPI concentrate is also effective in reversing DIC but not
approved for use. Several other infusion therapies have been
promoted by various centers. Many use heparin to prevent
ongoing thrombosis; however, heparin is a co-factor for
Available online http://ccforum.com/content/10/6/235
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Table 3
Effect of non-specific therapy on coagulation and fibrinolysis
Plasma infusion Plasma exchange
Restores procoagulant factors Restores procoagulant factor homeostasis
Restores anticoagulant factors (protein C, antithrombin III, TFPI) Restores anticoagulant factor homeostasis (protein C, antithrombin III, TFPI)
Restores prostacyclin Restores prostacyclin homeostasis
Restores tPA Restores tPA homeostasis
Restores ADAMTS 13 Restores ADAMTS 13 homeostasis
Removes ADAMTS 13 inhibitors
Removes ultra-large vWF multimers
Removes tissue factor
Removes excess PAI-1
PAI, plasminogen activator inhibitor type I; TFPI, tissue factor pathway inhibitor; tPA, tissue plasminogen activator; vWF, von Willebrand factor.
Figure 4
Specific therapies used to reverse or promote thrombosis and promote
or stop fibrinolysis. Therapies used to reverse thrombosis include
protein C concentrate (prot C), activated protein C (APC), tissue
factor pathway inhibitor (TFPI), antithrombin III, heparin, and thrombin
inhibitors such as argatroban and hyarudin. Therapies used to promote
thrombosis include activated factor VII. Therapies used to promote
fibrinolysis include tissue plasminogen activator (TPA), streptokinase,
urokinase, and defibrinopeptide. Therapies used to stop fibrinolysis
include aminocaproic acid, tranexamine, and aprotinin. 
PAI, plasminogen activator inhibitor type I.antithrombin III and, therefore, does not prevent clotting
efficiently if antithrombin III levels are low. Also, combined use
of heparin and antithrombin III concentrate can cause an
increased tendency to bleeding and actually increase
mortality. Prostacyclin infusion can improve microcirculatory
flow and decrease platelet thromboses. Other infusion
therapies with similar effects include nitroglycerin,
nitroprusside, milrinone, amrinone, and pentoxyfilline. Several
investigators have reported that fibrinolytic therapy with tissue
plasminogen activator, urokinase, or streptokinase leads to
remarkable restoration of limb perfusion and unexpected
survival with purpura fulminans. Continued use of urokinase
requires intermittent plasma infusion to replace depleted
plasminogen. The untoward complication of continued use of
fibrinolytic therapies can be bleeding if exogenous
plasminogen activator activity is far greater than endogenous
plasminogen activator inhibitor activity. It is likely prudent to
maintain higher platelet counts and pro-coagulant factor
levels (for example, platelet, fresh frozen plasma, and
cryoprecipitate infusion) when using fibrinolytic therapies. If
patients develop life-threatening bleeding from these
therapies, then one can consider anti-fibrinolytic therapies,
including aminocaproic acid, tranexamine, and aprotinin.
Recently, Ono and colleagues [24] reported that the degree
of ADAMTS 13 deficiency in DIC patients is associated with
both the degree of renal failure and the likelihood of
resolution of renal failure. Plasma exchange is a non-specific
therapy that has been reported by several centers to be
effective for reversal of DIC. The theory behind this therapy is
straightforward. If DIC is caused by increased circulating
tissue factor and plasminogen activator inhibitor activity,
reduced antithrombin III, protein C, protein S, prostacyclin
activity, and ADAMTS 13 activity, then why not simul-
taneously correct each of the abnormalities without causing
fluid overload? Plasma exchange is performed using 1½
volume exchange, which replaces approximately 78% of host
plasma. An aPTT >50 seconds predicts poor outcome in
meningococcemia. Plasma exchange reversed coagulopathy
and resulted in survival in seven out of nine children with
meningococcus-associated purpura fulminans who had a
predicted mortality of greater than 90% based on prolonged
PTT [36]. Interestingly, aPTT was corrected because factor II,
V, VII, and VIII levels were restored, but protein C and
antithrombin III levels were only minimally increased by
plasma exchange. These authors did not measure the effect
of plasma exchange on ADAMTS 13 levels. Attainment of
protein C levels of 0.25 IU/ml is associated with normalization
of coagulation in neonates with congenital purpura fulminans.
Supplementation of plasma exchange with protein C and
antithrombin III might be efficacious in patients with con-
sumptive microangiopathy.
Secondary TMA can be diagnosed in critically ill patients with
new-onset thrombocytopenia, organ failure, and elevated
LDH and an underlying predisposing condition (Table 1).
Poor outcomes of these processes are well documented.
Favorable responses of adults and children with secondary
TMA have been found with the use of the TTP-based plasma
exchange therapy protocol. The biological plausibility for
positive effects of plasma exchange in patients with TTP or
DIC has been discussed; the biological plausibility for
therapeutic effect in patients with secondary TMA is similar.
Plasma exchange normalizes plasminogen activator inhibitor
activity allowing endogenous tissue plasminogen activator to
lyse fibrin thrombi in a controlled and progressive fashion
without bleeding. Plasma exchange also has a beneficial
effect on vWF pathophysiology. It removes ADAMTS 13
inhibitors and ultra-large vWF multimers, restores ADAMTS
13 activity, and improves organ function.
Because protein C is an inhibitor of plasminogen activator
type 1 activity, its use could also have a role in children with
TAMOF with and without prolonged PT/aPTT. Darmon and
colleagues [51] recently reported that plasma exchange for a
median of 9 days reduced multiple organ failure and improved
survival in critically ill patients with TAMOF caused by
secondary TMA compared to plasma infusion therapy alone.
In this regard, a single center study in adults with severe
sepsis using plasma exchange therapy for a median of 3 days
showed a reduction in mortality from 54% to 33%, with an
absolute relative risk reduction of 20.5% and a number of
patients needed to treat to save one patient equal to 4.9 [25].
Interpreting the literature on therapy for
TAMOF
The medical literature on therapy for patients with TAMOF is
growing. Activated protein C studies in adults and children
show it has the best effect in patients with severe sepsis and
DIC. The bleeding risk can be minimized by correcting
thrombocytopenia (maintaining platelet counts >30,000/m3)
with platelet transfusion and prolonged PT/PTT with FFP
infusion, before administering the drug. Clinical studies
testing plasma exchange have consistently shown positive
results in patients with TAMOF (TTP, secondary TMA) but
varied results in those with severe sepsis. Its use for
treatment of TTP is universally accepted; however, it is
important to note that therapy is continued until restoration of
platelet count, usually after 18 days of therapy. Darmon and
colleagues [51] demonstrated improved outcomes (reduction
in mortality from 40% to 0%) when comparing plasma
exchange for a median of 9 days compared to plasma
infusion. Similar to the experience in the TTP trials [18], these
authors found that recrudescence was common when plasma
exchange was attempted for more abbreviated periods of
time. Reeves and colleagues [49] performed a clinical trial of
continuous plasma filtration without full plasma replacement
for 36 hours in adults and children with severe sepsis and
found no benefit. The authors did not state whether their
patients had TAMOF; however, one would not expect a
benefit if TTP-like pathophysiology was the target (this needs
up to 18 days of treatment), nor if DIC pathophysiology was
Critical Care    Vol 10 No 6 Nguyen and Carcillo
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deficient anti-coagulant proteins). Interestingly, Busund and
colleagues [25] performed a trial of daily centrifugation-based
full plasma exchange for three days in patients with severe
sepsis and showed improved survival. Stegmayr and
colleagues [50] also reported improved outcome with one to
three treatments of centrifugation-based plasma exchange in
severe sepsis. Improvement was less likely to be from
reversal of TTP-like pathophysiology (due to short duration)
and more likely to be from reversal of DIC pathophysiology.
We interpret these findings as follows. Activated protein C
(four day infusion) should be used to treat adult severe sepsis
with greatest benefit expected in the DIC population [26].
Plasma exchange should be performed on a daily basis for
patients with TTP [51] or secondary TMA [18] until resolution
of thrombocytopenia (a median 9 to 16 days) and recrudes-
cence of thrombocytopenia should be treated with resump-
tion of daily plasma exchange therapy.
Conclusion
A consensus is developing that reversal of microvascular
thrombosis is a therapeutic target in patients with TAMOF
defined by the clinical triad of new onset thrombocytopenia,
multiple organ failure, and elevated LDH levels. As with all
therapeutic targets, the underlying cause of disease must be
removed for the therapy to have long-term effects. Microvascular
thrombosis is associated with systemic insults, including shock,
infection, drugs, toxins, and radiation. For therapies directed at
microangiopathy to be beneficial, shock must be reversed,
infection eradicated and removed, and precipitating drugs,
toxins, and radiation stopped. Anti-thrombotic/fibrinolytic
therapies can only be expected to have beneficial effects on
outcome if and when these tasks have been accomplished.
New-onset thrombocytopenia is a clinical indicator of TMA in
patients with MOF, and resolution of thrombocytopenia is an
indicator of resolving TMA. Therefore, resolution of
thrombocytopenia is the goal for directed use of therapy.
Activated protein C use is associated with improved
outcomes in children and adults with severe sepsis and DIC;
however, activated protein C does not address the deficiency
of ADAMTS 13 in the severest forms of DIC, nor in TTP or
secondary TMA. Thus, development of human recombinant
ADAMTS 13 could be an important drug discovery. There is
also an important need to develop clinical laboratory testing
that allows bedside determination of ADAMTS 13 activity. At
this time, clinical trials support the use of steroids and
intensive daily centrifugation-based plasma exchange therapy
to reverse TTP/DIC/secondary TMA, and improve survival for
patients with TAMOF [18,25,51].
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